Advertisement
Document › Details
Merck KGaA. (9/29/20). "Press Release: Press Release as a Result of the Ad-hoc Announcement of September 29, 2020". Darmstadt.
Region | United States (USA) | |
Organisation | EMD Serono Inc. | |
Group | Merck (DE) (Group) | |
Organisation 2 | Biogen Inc. (Nasdaq: BIIB) | |
Group | Biogen (Group) | |
Product | Rebif® | |
Product 2 | IP services | |
Person | Segeberg, Friederike (Merck (DE) 202002 Head Media Relations) | |
Merck has just published the following ad-hoc announcement in accordance with Art. 17 of the German Market Abuse Regulation:
In the United States Merck KGaA’s subsidiary EMD Serono, Inc. (Merck) is involved in a US patent dispute with Biogen Inc., United States (Biogen). Biogen sued Merck for damages in connection with a patent infringement caused by Merck’s product Rebif before the U.S. District Court New Jersey, Newark. Merck defended itself against the allegations and brought a countersuit claiming that Biogen’s patent is invalid. In February 2018 a jury declared Biogen’s patent invalid vis-à-vis Merck. The jury verdict was overturned by the District Court Judge, who upheld the validity of Biogen’s patent. Merck filed a complaint with the U.S. Court of Appeals for the Federal Circuit against this ruling.
On 28 September 2020 the U.S. Court of Appeals for the Federal Circuit set aside the decision of the District Court Judge, invalidated Biogen’s patent and instructed the District Court to reinstate the jury verdict.
Therefore, Merck KGaA has decided today to reverse the provisions for the patent dispute proceedings in the amount of EUR 365 million. Thereof, up to a mid to high double-digit million amount might be booked into the financial result.
Merck KGaA will adjust its forecasts accordingly as part of its regular financial reporting.
For more information, please contact Friederike Segeberg
+49 6151 72-6328
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
Record changed: 2023-06-05 |
Advertisement
More documents for Merck (DE) (Group)
- [1] Merck KGaA. (6/24/24). "Press Release: Merck Provides Update on Xevinapant Program in Locally Advanced Head and Neck Cancer [ Not intended for UK-, US- or Canada-based media ]". Darmstadt....
- [2] Merck KGaA. (5/29/24). "Press Release: Merck Signs MoU with KAIST to Advance Scientific Collaboration". Darmstadt....
- [3] Merck KGaA. (5/22/24). "Press Release: Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million". Darmstadt....
- [4] Merck KGaA. (4/25/24). "Press Release: Merck Invests More Than € 300 Million in New Life Science Research Center in Germany". Darmstadt....
- [5] Outrun Therapeutics Ltd.. (4/18/24). "Press Release: Outrun Therapeutics Launches with a $10m Seed Financing from M Ventures and MP Healthcare Venture Management to Develop a Protein Stabilisation Pipeline". Dundee....
- [6] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
- [7] BioGeneration Ventures B.V.. (4/2/24). "Press Release: BGV Appoints Peter Halle, PhD as Venture Partner". Amsterdam....
- [8] C4 Therapeutics, Inc.. (3/4/24). "Press Release: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins". Watertown, MA....
- [9] Precirix N.V.. (2/29/24). "Press Release: Tom Plitz Commences Role as Chief Executive Officer of Precirix". Brussels....
- [10] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top